Digital China Health (China)

Digital China Health (神州医疗) is a Chinese health technology company headquartered in Beijing. It positions itself as a leader in medical big data and medical artificial intelligence, with the stated ambition of becoming an internationally leading enterprise in these fields. The company provides advanced products and solutions across the entire health and medical ecosystem, serving hospitals, public health institutions, pharmaceutical companies, and insurers. The company's core business lines include medical big data, medical artificial intelligence, precision medicine, and digital services for pharmaceutical companies. In medical big data, it offers full-chain data governance technology and capabilities, and has built or participated in national-level data platforms including the National Cancer Big Data Platform, the Chinese National Rare Disease Registry System (NRDRS), the National Cardiovascular Big Data Platform, and the China Kidney Disease Big Data Platform. Its medical AI work focuses on vertical medical large language models developed with academician teams, national medical centers, and top-tier hospitals. In precision medicine, it leverages its self-developed iCMDB multi-omics medical knowledge base and biobank to provide one-stop precision medicine services for clinical departments and diagnostic laboratories. Its pharmaceutical digital services bridge clinical researchers and pharmaceutical enterprises, offering technical services from data to insight. According to its official website, Digital China Health has data governance coverage of 700 million person-times, has built more than 5 national specialty disease big data platforms, participated in over 45 national research projects and major programs, and serves more than 700 tertiary hospitals and over 3,000 clients across hospitals, public health, pharmaceutical companies, and insurance. It also lists more than 20 global strategic partners, including Philips, IQVIA, the Stanley Center of the Broad Institute, Dana-Farber, QIAGEN, Congenica, Singapore's Agency for Science, Technology and Research, Public Health England, AMIA, SNOMED, Mount Sinai Hospital, and Singapore General Hospital. Its hospital clients include Peking Union Medical College Hospital, Chinese PLA General Hospital, Peking University Cancer Hospital, Fudan University Affiliated Children's Hospital, Shanghai Children's Hospital, and many other leading Chinese hospitals. The company has developed a range of vertical medical AI models, including models for peritoneal dialysis, pediatric and adolescent obesity ("Fuxing"), women's tumors ("Tongji·Mulan"), chronic kidney disease management ("Zhishen"), neonatal critical care ("Aixin Zhihu"), children's brain health ("Qizhi"), pediatric rare diseases ("Nezha·Lingtong"), cerebral hemorrhage ("Naoruikang"), fertility-friendly care ("Zhihui"), and birth defect prevention ("Huiyu Tongxing"). It also offers AI hospital, AI maternal and child hospital, AI medical school, and AI city-level medical brain solutions. In precision medicine, it provides pharmacogenomics products, reporting systems and knowledge databases, nucleic acid molecular hybridization instruments, chemiluminescence products, and fully automated chemiluminescence immunoassay analyzers. Its pharmaceutical digital services include real-world research and pharmacovigilance systems. Digital China Health is active in international academic and industry events. In 2026, it participated in the 18th World Public Health Congress, where its city medical brain innovation system was selected for an oral presentation, and its AI medical school appeared at the 2026 SCO Digital Economy Forum. It also collaborates with international institutions such as the UK National Disease Registration and Cancer Analysis Centre, the Sanger Institute's Congenica, and the Broad Institute's Stanley Center for Psychiatric Research.

Digital China Health (神州医疗) is a Beijing-based health technology company. While its exact founding year is not specified in the available evidence, the company has established itself as a significant player in China's medical big data and medical AI sectors. It is known for building and operating national-level health data platforms, including the National Cancer Big Data Platform, the Chinese National Rare Disease Registry System (NRDRS), the National Cardiovascular Big Data Platform, and the China Kidney Disease Big Data Platform. These platforms integrate clinical, imaging, laboratory, omics, follow-up, biospecimen, and literature data to support clinical quality control, early screening, diagnosis, treatment, prognosis, and government decision-making. The company has developed proprietary technologies such as the iCMDB multi-omics medical knowledge base and has formed partnerships with international organizations including Philips, IQVIA, the Stanley Center of the Broad Institute, Dana-Farber, QIAGEN, Congenica, Singapore's Agency for Science, Technology and Research, Public Health England, AMIA, SNOMED, Mount Sinai Hospital, and Singapore General Hospital. It collaborates with the UK National Disease Registration and Cancer Analysis Centre and has deep cooperation with Congenica (Sanger Institute) and the Stanley Center for Psychiatric Research (Broad Institute) on bioinformatics analysis and interpretation technologies. In recent years, Digital China Health has focused on developing vertical medical large language models in collaboration with academician teams, national medical centers, and tertiary hospitals. These models cover various specialties, including peritoneal dialysis, pediatric obesity, women's tumors, chronic kidney disease, neonatal critical care, children's brain health, pediatric rare diseases, cerebral hemorrhage, fertility, and birth defects. The company also offers AI hospital, AI maternal and child hospital, AI medical school, and AI city-level medical brain solutions. In 2026, it participated in the 18th World Public Health Congress and the 2026 SCO Digital Economy Forum, showcasing its innovations in medical AI and public health.

• Chongqing Medical University Affiliated Second Hospital and Digital China Health release metabolic comorbidity large model

• Digital China Health AI Medical School showcased at 2026 SCO Digital Economy Forum

• Digital China Health presents at 18th World Public Health Congress

• Digital China Health city medical brain selected for oral presentation at 18th World Public Health Congress

Leader in medical big data and medical artificial intelligence, providing advanced products and solutions across the entire health and medical ecosystem.

• National Cancer Big Data Platform

  A national platform integrating clinical, imaging, laboratory, omics, follow-up, biospecimen, and literature data for cancer research, screening, diagnosis, treatment, and government decision-making.

• Chinese National Rare Disease Registry System (NRDRS)

  A nationwide rare disease registration system built as part of the National Key R&D Program's Precision Medicine initiative.

• National Cardiovascular Big Data Platform

  A cardiovascular big data collaborative research project initiated by the China Cardiovascular Health Alliance.

• China Kidney Disease Big Data Platform

  A kidney disease big data platform built by Digital China Health.

• iCMDB multi-omics medical knowledge base

  A self-developed multi-omics medical knowledge base supporting precision medicine services.

• Medical vertical large models

  A series of specialty-specific AI models developed with academician teams and top hospitals, covering areas such as peritoneal dialysis, pediatric obesity, women's tumors, chronic kidney disease, neonatal critical care, children's brain health, pediatric rare diseases, cerebral hemorrhage, fertility, and birth defects.

• AI Hospital / AI Maternal and Child Hospital / AI Medical School / AI City-level Medical Brain

  AI-enabled solutions for hospitals, maternal and child health institutions, medical education, and city-level health management.

• Precision medicine products

  Includes pharmacogenomics products, reporting systems and knowledge databases, nucleic acid molecular hybridization instruments, chemiluminescence products, and fully automated chemiluminescence immunoassay analyzers.

• Pharmaceutical digital services

  Real-world research and pharmacovigilance systems bridging clinical researchers and pharmaceutical enterprises.

1. 1神州医疗-医疗大数据与人工智能领军企业|神州医疗科技股份有限公司官网dhctech.com
2. 2国家肿瘤大数据平台dhctech.com
3. 3化学发光产品dhctech.com
4. 4公司新闻dhctech.com
5. 5Digital China Health (China) - Wikidatawikidata.org